Imunon, Inc. Approves Executive Stock-Based Compensation Programs

On August 11, 2026, Imunon, Inc. reported that its Compensation Committee and Board of Directors approved new compensatory programs for key executive officers. Under these programs, executives can elect to receive a portion of their base salary in shares of common stock rather than cash, supplemented by additional incentive shares. Specifically, President and CEO Stacy Lindborg may elect to receive up to 50% of her salary in stock, with additional shares ranging from 12% to 35% of the net stock payment value depending on the pay date. Executive Chairman Michael Tardugno may receive up to 100% of his salary in stock, with additional incentive shares between 20% and 40%. Chief Medical Officer Douglas Faller may elect up to 40% in stock, with a 12% to 15% incentive match. Shares for Dr. Lindborg and Mr. Tardugno are exempt from registration under Section 4(a)(2), while Dr. Faller’s shares will be issued under the Company’s 2018 Stock Incentive Plan. These arrangements are scheduled to run through September 25, 2026.